By Colin Kellaher Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints. The Swiss pharma company ROG, -3.72% Read more By Michael Susin GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival. The Read more AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast Read more Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary Read more A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are Read more A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are Read more GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine candidate for adults aged over 60 years met its primary endpoint. The U.K.-based maker of Read more Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and Biogen Inc. said their experimental Alzheimer’s disease drug significantly slowed progression of the disease in Read more Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval. The pharmaceutical companies Read more
Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints
GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint
AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
Novartis hemoglobinuria trial meets two primary endpoints
Fresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
Fresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
GSK respiratory syncytial virus vaccine Phase 3 trial meets primary endpoint
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Alzheimer’s drug from Eisai, Biogen shows promise in large trial